公开(公告)号：US10654921B2

公开(公告)日：2020-05-19

申请号：US16321020

申请日：2017-07-26

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Simeon Cua ,  Andre Boon Hwa Choo ,  Heng Liang Tan ,  Wey Jia Fong ,  Vanessa Mei Yee Ding ,  Leonard Wen Yan Leong

IPC: A61K39/395 ,  C07K16/18 ,  A61K47/68 ,  A61P35/00 ,  G01N33/574 ,  A61K31/282 ,  A61K31/337 ,  A61K31/5377 ,  A61K38/17 ,  C07K14/705 ,  A61K39/00

Abstract: The present invention relates to an antigen-binding protein, preferably a monoclonal antibody, against annexin A2 (ANXA2), comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequence GYSITSGYSWH, a VHCDR2 of sequence YIHYSGSTKYNPSLKS and a VHCDR3 of sequence GSNYGFDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSNDQKNYLA, a VLCDR2 of sequence WASIRES, and a VLCDR3 of sequence QQYYIYPLT. Also provided is an ANXA2 binding protein comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequence VYSITSGYSWH; a VHCDR2 of sequence YIHYSGSTKYNPSLKS, and a VHCDR3 of sequence GTDNAVDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSSNQKNYLA, a VLCDR2 of sequence WASSRES, and a VLCDR3 of sequence QQYYIYPLT. The antibodies preferably bind to an N-linked glycan on ANXA2, and are internalised upon binding. They may be conjugated with cytotoxins and may be used in the treatment or detection of cancer.

公开(公告)号：US11697681B2

公开(公告)日：2023-07-11

申请号：US16848828

申请日：2020-04-14

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Simeon Cua ,  Andre Boon Hwa Choo ,  Heng Liang Tan ,  Wey Jia Fong ,  Vanessa Mei Yee Ding ,  Leonard Wen Yan Leong

IPC: A61K39/395 ,  C07K16/18 ,  A61K47/68 ,  A61P35/00 ,  G01N33/574 ,  A61K31/282 ,  A61K31/337 ,  A61K31/5377 ,  A61K38/17 ,  C07K14/705 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K31/282 ,  A61K31/337 ,  A61K31/5377 ,  A61K38/1774 ,  A61K39/3955 ,  A61K47/6819 ,  A61K47/6825 ,  A61K47/6843 ,  A61P35/00 ,  C07K14/70521 ,  G01N33/574 ,  A61K2039/505 ,  A61K2039/572 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/90 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33 ,  G01N2333/4718

Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GYSITSGYSWH; a VHCDR2 having the amino acid sequence YIHYSGSTKYNPSLKS and a VHCDR3 having the amino acid sequence GSNYGFDY; and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLYSNDQKNYLA, a VLCDR2 having the amino acid sequence WASIRES, and a VLCDR3 having the amino acid sequence QQYYIYPLT. The present invention also relates to an antigen-binding protein, or an antigen-binding fragment thereof, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence VYSITSGYSWH; a VHCDR2 having the amino acid sequence YIHYSGSTKYNPSLKS, and a VHCDR3 having the amino acid sequence GTDNAVDY; and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLYSSNQKNYLA, a VLCDR2 having the amino acid sequence WAS SRES, and a VLCDR3 having the amino acid sequence QQYYIYPLT. Compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof and kits comprising the antigen-binding protein, or antigen-binding fragment thereof are also provided.